Market Place
Sourcing Support
Nxera Pharma Reports Q3 & 9-Month 2024 Operational Results
01 Nov 2024 //
GLOBENEWSWIRE
Nxera Pharma Wins Biotech Company and Financing Awards 2024
23 Oct 2024 //
GLOBENEWSWIRE
Nxera Pharma inks deal with Handok to distribute PIVLAZ in South Korea
16 Apr 2024 //
BIOSPECTRUM ASIA
Nxera Pharma is the New Name for Sosei Group
31 Mar 2024 //
GLOBENEWSWIRE
Sosei Confirms Re-election & Approval of Change the Name to Nxera Pharma
27 Mar 2024 //
GLOBENEWSWIRE
Boehringer pays €25M for option to Sosei’s schizophrenia drug
11 Mar 2024 //
FIERCE BIOTECH
Sosei Heptares™ President & CEO Chris Cargill Wins Executive of the Year
18 Oct 2023 //
GLOBENEWSWIRE
Sosei Heptares and Verily Nominate First G-protein-coupled receptor
04 Oct 2023 //
BUSINESSWIRE
Sosei Heptares Adds World-leading Expertise to its Scientific Advisory Board
20 Sep 2023 //
GLOBENEWSWIRE
Sosei Heptares and Cancer Research UK Announce the Dosing of the First
10 Aug 2023 //
GLOBENEWSWIRE
Sosei Heptares Consolidated Results for Q2 and First Half of 2023
04 Aug 2023 //
GLOBENEWSWIRE
Sosei Heptares Webinar Presentation for Q2 FY2023 Financial Results
11 Jul 2023 //
GLOBENEWSWIRE
Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149
02 Jul 2023 //
GLOBENEWSWIRE
Everyone wants in on GLP-1: Pfizer doses first patient in PhII trial
21 Dec 2022 //
ENDPTS
Sosei Heptares` Partner Pfizer Progresses its Oral GLP-1 Receptor PF-07081532
20 Dec 2022 //
GLOBENEWSWIRE
Lilly Pens $730M Deal with Sosei Heptares to Push GPCRs
17 Dec 2022 //
FIERCEBIOTECH
Sosei Heptares Operational Highlights and Consolidated Results for the 3Q
10 Nov 2022 //
GLOBENEWSWIRE
Sosei Heptares’ President & CEO and Head of UK R&D to in a ‘Fireside Chat’
08 Nov 2022 //
GLOBENEWSWIRE
Sosei’s Partner Neurocrine Initiates Phase 2 Study Evaluating NBI-1117568
27 Oct 2022 //
GLOBENEWSWIRE
Sosei Heptares Consolidated Results for the Q2 and First Half of 2022
10 Aug 2022 //
GLOBENEWSWIRE
Sosei Heptares’ Selective M4 Receptor Agonist Advancing into PII Development
04 Aug 2022 //
GLOBENEWSWIRE
AbbVie taps Sosei Heptares GPCR expertise with $1.2bn+ alliance
03 Aug 2022 //
PHARMAPHORUM
Sosei Heptares partners with Cancer Research UK to bring its drug to trial
23 Jul 2022 //
ENDPTS
Cancer Research UK &Sosei Heptares sign agreement to advance cancer immunotherap
21 Jul 2022 //
GLOBENEWSWIRE
Sosei Heptares Webinar Presentation for Q2 FY2022 Financial Results
11 Jul 2022 //
GLOBENEWSWIRE
Sosei Heptares Expands UK R&D Operations to Second Site within Cambridge
26 May 2022 //
GLOBENEWSWIRE
Sosei Heptares and Kallyope Enter Collaboration for Novel GI GPCR Targets
17 May 2022 //
GLOBENEWSWIRE
Sosei Heptares Operational Highlights and Consolidated Results
13 May 2022 //
GLOBENEWSWIRE
Sosei Heptares Confirms Senior Leadership Changes
24 Mar 2022 //
GLOBENEWSWIRE
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2021
10 Feb 2022 //
GLOBENEWSWIRE
Sosei Heptares Webinar Presentation for FY2021 Financial Results
21 Jan 2022 //
GLOBENEWSWIRE
Sosei Heptares and Verily to collaborate on immune-mediated disease treatments
06 Jan 2022 //
PHARMATIMES
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience
16 Dec 2021 //
GLOBENEWSWIRE
Sosei, Twist Partner for Novel Therapeutic Antibodies Against GPCR Targets
16 Dec 2021 //
BUSINESSWIRE
University of Glasgow reveals drug design for new Alzheimer’s treatments
25 Nov 2021 //
PHARMATIMES
Neurocrine gets selective in schizophrenia
23 Nov 2021 //
EVALUATE
Neurocrine pens $2.6B biobucks pact with Sosei Heptares
23 Nov 2021 //
FIERCEBIOTECH
AstraZeneca scraps midphase drugs from $1B buyout, Heptares pact
13 Nov 2021 //
FIERCEBIOTECH
Sosei Heptares inks collaboration with InveniAI
07 Jul 2021 //
PHARMABIZ
Sosei Heptares and InveniAI Enter Collaboration
06 Jul 2021 //
PR NEWSWIRE
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist
23 Jun 2021 //
PRNEWSWIRE
Sosei Heptares to receive US$2.5 million milestone payment from Formosa
11 Mar 2021 //
PRNEWSWIRE
Sosei Heptares spin-off company Orexia Therapeutics merged
16 Feb 2021 //
PRNEWSWIRE
Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches
01 Feb 2021 //
PRNEWSWIRE
Sosei Heptares and Metrion Biosciences to collaborate on structure-based drug
01 Feb 2021 //
PHARMAFILE
AI-driven drug discovery collaboration to tackle neurological diseases
12 Jan 2021 //
OUTSOURCING-PHARMA
Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-driven Drug
11 Jan 2021 //
PRNEWSWIRE
AbbVie bails on Sosei Heptares pact for novel neurology candidates in blow
06 Jan 2021 //
ENDPTS
Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
04 Jan 2021 //
BIOSPACE
Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
04 Jan 2021 //
PRNEWSWIRE
Sosei, GSK agree to develop inflammatory bowel disease treatment
21 Dec 2020 //
REUTERS
Sosei Heptares and Biohaven Enter Global Collaboration and Agreement
01 Dec 2020 //
PRNEWSWIRE
Sosei Heptares’ COVID-19 programme advances promising molecules
20 Nov 2020 //
PHARMATIMES
Sosei Heptares and Aditum Bio to advance clinical for neurological diseases
03 Nov 2020 //
BIOSPECTRUMASIA
Sosei Heptares and Aditum Bio to advance clinical program
02 Nov 2020 //
BIOSPECTRUMASIA
Japan`s Sosei allies ex-Novartis team to develop neurological drug pipeline
30 Oct 2020 //
REUTERS
Sosei Heptares scores $5m milestone payment from Pfizer
29 Sep 2020 //
PHARMA TIMES
Sosei Heptares Successfully Raises US$200 million in International Offering
16 Jul 2020 //
PRNEWSWIRE
Sosei Heptares notes Enerzair® approval in Japan – the world’s first approval
29 Jun 2020 //
PRESS RELEASE
